Eli Lilly and Company (LLY)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 935.02 |
| Open | 937.01 |
| Bid | 925.00 x 900 |
| Ask | 926.50 x 900 |
| Day's range | 922.10 - 942.35 |
| 52-week range | 516.57 - 972.53 |
| Volume | |
| Avg. volume | 3,214,900 |
| Market cap | 831.733B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 113.62 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.56%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
- Zacks
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
- Zacks
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
- Investor's Business Daily
Is Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?
Eli Lilly halved the price of a new version of its weight-loss drug, Zepbound. Is Eli Lilly stock a buy right now?
© 2024 Yahoo. All rights reserved.